{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:40:47Z","timestamp":1776436847392,"version":"3.51.2"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"vor","delay-in-days":364,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2018]]},"DOI":"10.6061\/clinics\/2018\/e490s","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T09:51:58Z","timestamp":1539683518000},"page":"e490s","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"S1","title":["Carcinoid syndrome: update on the pathophysiology and treatment"],"prefix":"10.1016","volume":"73","author":[{"given":"Anezka C. Rubin","family":"de Celis Ferrari","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o","family":"Glasberg","sequence":"additional","affiliation":[]},{"given":"Rachel P","family":"Riechelmann","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"4","key":"10.6061\/clinics\/2018\/e490s_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000381930","article-title":"Carcinoid Heart Disease: From Pathophysiology to Treatment-'Something in the Way It Moves\u2019","volume":"101","author":"Grozinsky-Glasberg","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.6061\/clinics\/2018\/e490s_bib2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3332\/ecancer.2016.662","article-title":"Complications from carcinoid syndrome: review of the current evidence","volume":"10","author":"Mota","year":"2016","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"10.6061\/clinics\/2018\/e490s_bib3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.6061\/clinics\/2018\/e490s_bib4","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.clinthera.2017.09.013","article-title":"Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl","volume":"39","author":"Anthony","year":"2017","journal-title":"Clin Ther"},{"issue":"12","key":"10.6061\/clinics\/2018\/e490s_bib5","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1634\/theoncologist.2017-0149","article-title":"Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients","volume":"22","author":"Shen","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.6061\/clinics\/2018\/e490s_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JGO.2015.002980","article-title":"Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs","volume":"3","author":"Singh","year":"2016","journal-title":"J Glob Oncol"},{"issue":"6","key":"10.6061\/clinics\/2018\/e490s_bib7","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"issue":"6","key":"10.6061\/clinics\/2018\/e490s_bib8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.clindermatol.2014.02.019","article-title":"Red face revisited: Flushing","volume":"32","author":"\u0130kizo\u011flu","year":"2014","journal-title":"Clin Dermatol"},{"issue":"10","key":"10.6061\/clinics\/2018\/e490s_bib9","first-page":"594","article-title":"Pathophysiological causes and clinical significance of flushing","volume":"50","author":"Ray","year":"1993","journal-title":"Br J Hosp Med"},{"issue":"5","key":"10.6061\/clinics\/2018\/e490s_bib10","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4158\/EP14464.DSC","article-title":"AACE\/ACE disease state clinical review: diagnosis and management of midgut carcinoids","volume":"21","author":"Liu","year":"2015","journal-title":"Endocr Pract"},{"issue":"6","key":"10.6061\/clinics\/2018\/e490s_bib11","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1210\/jcem-70-6-1702","article-title":"Plasma substance-P in neuroendocrine tumors and idiopathic flushing: the value of pentagastrin stimulation tests and the effects of somatostatin analog","volume":"70","author":"Vinik","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"10.6061\/clinics\/2018\/e490s_bib12","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/cncr.30633","article-title":"Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome","volume":"123","author":"Shi","year":"2017","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.6061\/clinics\/2018\/e490s_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000051853","article-title":"Tumor markers in neuroendocrine tumors","volume":"62","author":"Eriksson","year":"2000","journal-title":"Digestion"},{"key":"10.6061\/clinics\/2018\/e490s_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000382053","article-title":"Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms","volume":"44","author":"Boutzios","year":"2015","journal-title":"Front Horm Res"},{"issue":"9130","key":"10.6061\/clinics\/2018\/e490s_bib15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(98)02286-7","article-title":"Carcinoid tumour","volume":"352","author":"Caplin","year":"1998","journal-title":"Lancet"},{"key":"10.6061\/clinics\/2018\/e490s_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1749-6632.1997.tb48183.x","article-title":"Heterogeneity of 5-HT receptors mediating secretion in the human intestine","volume":"812","author":"Borman","year":"1997","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.6061\/clinics\/2018\/e490s_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide","volume":"21","author":"Kulke","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"21","key":"10.6061\/clinics\/2018\/e490s_bib18","article-title":"Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med. 1993 Oct 7;329(15):1073-8","volume":"329","author":"von der Ohe","year":"1993","journal-title":"Erratum in: N Engl J Med"},{"issue":"9","key":"10.6061\/clinics\/2018\/e490s_bib19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3109\/00365528708991954","article-title":"Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements","volume":"22","author":"Oberg","year":"1987","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.6061\/clinics\/2018\/e490s_bib20","first-page":"133","article-title":"Carcinoid syndrome: a statistical evaluation of 748 reported cases","volume":"18","author":"Soga","year":"1999","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"10.6061\/clinics\/2018\/e490s_bib21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N Engl J Med"},{"issue":"8","key":"10.6061\/clinics\/2018\/e490s_bib22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/jso.23323","article-title":"Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients","volume":"107","author":"Massimino","year":"2013","journal-title":"J Surg Oncol"},{"key":"10.6061\/clinics\/2018\/e490s_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jclinane.2016.03.008","article-title":"Development of effective prophylaxis against intraoperative carcinoid crisis","volume":"32","author":"Woltering","year":"2016","journal-title":"J Clin Anesth"},{"key":"10.6061\/clinics\/2018\/e490s_bib24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3332\/ecancer.2017.716","article-title":"Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group","volume":"11","author":"Riechelmann","year":"2017","journal-title":"Ecancermedicalscience"},{"key":"10.6061\/clinics\/2018\/e490s_bib25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1749-6632.1994.tb17296.x","article-title":"Metastatic carcinoid tumors and the malignant carcinoid syndrome","volume":"733","author":"Kvols","year":"1994","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"10.6061\/clinics\/2018\/e490s_bib26","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1073\/pnas.94.10.5308","article-title":"Differences between males and females in rates of serotonin synthesis in human brain","volume":"94","author":"Nishizawa","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.6061\/clinics\/2018\/e490s_bib27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00213-003-1455-5","article-title":"Neuropsychological investigation into the carcinoid syndrome","volume":"168","author":"Russo","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.6061\/clinics\/2018\/e490s_bib28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/SLA.0b013e318288ff6d","article-title":"Cognitive impairment associated with carcinoid syndrome","volume":"259","author":"Pasieka","year":"2014","journal-title":"Ann Surg"},{"issue":"21","key":"10.6061\/clinics\/2018\/e490s_bib29","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJM196711232772101","article-title":"Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome","volume":"277","author":"Engelman","year":"1967","journal-title":"N Engl J Med"},{"issue":"1","key":"10.6061\/clinics\/2018\/e490s_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.6061\/clinics\/2018\/e490s_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-4632.2004.01959.x","article-title":"Pellagra: dermatitis, dementia, and diarrhea","volume":"43","author":"Hegyi","year":"2004","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.6061\/clinics\/2018\/e490s_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.beem.2015.09.005","article-title":"Carcinoid heart disease: Diagnosis and management","volume":"30","author":"Luis","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"10.6061\/clinics\/2018\/e490s_bib33","first-page":"55","article-title":"Carcinoid heart disease","volume":"39","author":"Steiner","year":"2003","journal-title":"Cesk Patol"},{"issue":"5603","key":"10.6061\/clinics\/2018\/e490s_bib34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.1078197","article-title":"Synthesis of serotonin by a second tryptophan hydroxylase isoform","volume":"299","author":"Walther","year":"2003","journal-title":"Science"},{"issue":"23","key":"10.6061\/clinics\/2018\/e490s_bib35","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"issue":"3","key":"10.6061\/clinics\/2018\/e490s_bib36","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1073\/pnas.83.3.674","article-title":"Stimulation of aortic smooth muscle cell mitogenesis by serotonin","volume":"83","author":"Nemecek","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.6061\/clinics\/2018\/e490s_bib37","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1161\/01.CIR.90.4.1919","article-title":"Mitogenic effect of serotonin on vascular endothelial cells","volume":"90","author":"Pakala","year":"1994","journal-title":"Circulation"},{"issue":"12","key":"10.6061\/clinics\/2018\/e490s_bib38","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/01.CIR.0000159356.42064.48","article-title":"Long-term serotonin administration induces heart valve disease in rats","volume":"111","author":"Gustafsson","year":"2005","journal-title":"Circulation"},{"issue":"4-5","key":"10.6061\/clinics\/2018\/e490s_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.etp.2008.03.005","article-title":"5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats","volume":"60","author":"Elangbam","year":"2008","journal-title":"Exp Toxicol Pathol"},{"issue":"5","key":"10.6061\/clinics\/2018\/e490s_bib40","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1369\/jhc.4A6500.2005","article-title":"5-Hydroxytryptamine (5HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats","volume":"53","author":"Elangbam","year":"2005","journal-title":"J Histochem Cytochem"},{"issue":"25","key":"10.6061\/clinics\/2018\/e490s_bib41","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1161\/01.CIR.0000074224.57016.01","article-title":"Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy","volume":"107","author":"Nebigil","year":"2003","journal-title":"Circulation"},{"issue":"17","key":"10.6061\/clinics\/2018\/e490s_bib42","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1073\/pnas.97.17.9508","article-title":"Serotonin 2B receptor is required for heart development","volume":"97","author":"Nebigil","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.6061\/clinics\/2018\/e490s_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCRESAHA.108.180976","article-title":"Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy","volume":"104","author":"Jaffr\u00e9","year":"2009","journal-title":"Circ Res"},{"issue":"6","key":"10.6061\/clinics\/2018\/e490s_bib44","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1074\/jbc.271.6.3141","article-title":"Ras involvement in signal transduction by the serotonin 5-HT2B receptor","volume":"271","author":"Launay","year":"1996","journal-title":"J Biol Chem"},{"issue":"6","key":"10.6061\/clinics\/2018\/e490s_bib45","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/S0002-9440(10)64497-5","article-title":"Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells","volume":"161","author":"Xu","year":"2002","journal-title":"Am J Pathol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e490s_bib46","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ijcard.2008.02.019","article-title":"Carcinoid heart disease","volume":"129","author":"Gustafsson","year":"2008","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e490s_bib47","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000318014","article-title":"Activin A in carcinoid heart disease: a possible role in diagnosis and pathogenesis","volume":"92","author":"Bergestuen","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"39","key":"10.6061\/clinics\/2018\/e490s_bib48","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.3748\/wjg.v13.i39.5208","article-title":"CTGF, intestinal stellate cells and carcinoid fibrogenesis","volume":"13","author":"Kidd","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.6061\/clinics\/2018\/e490s_bib49","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.22725","article-title":"Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1","volume":"109","author":"Kidd","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.6061\/clinics\/2018\/e490s_bib50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardiores.2004.04.030","article-title":"TGF-beta1 and angiotensin networking in cardiac remodeling","volume":"63","author":"Rosenkranz","year":"2004","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.6061\/clinics\/2018\/e490s_bib51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1037\/0022-3514.80.1.68","article-title":"Emotions in collectivist and individualist contexts","volume":"80","author":"Mesquita","year":"2001","journal-title":"J Pers Soc Psychol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e490s_bib52","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/cvr\/cvv188","article-title":"Fanning the flames: inflammation in cardiovascular diseases","volume":"107","author":"Libby","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.6061\/clinics\/2018\/e490s_bib53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/qjmed\/hcp191","article-title":"Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine ('carcinoid\u2019) tumours of the small bowel","volume":"103","author":"Druce","year":"2010","journal-title":"QJM"},{"issue":"1","key":"10.6061\/clinics\/2018\/e490s_bib54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/bjs.10333","article-title":"Clinical signs of fibrosis in small intestinal neuroendocrine tumours","volume":"104","author":"Daskalakis","year":"2017","journal-title":"Br J Surg"},{"issue":"1","key":"10.6061\/clinics\/2018\/e490s_bib55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.hoc.2015.09.001","article-title":"Surgical Treatment of Small Bowel Neuroendocrine Tumors","volume":"30","author":"Farley","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.6061\/clinics\/2018\/e490s_bib56","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2214\/ajr.164.2.7839976","article-title":"Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation","volume":"164","author":"Pantongrag-Brown","year":"1995","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.6061\/clinics\/2018\/e490s_bib57","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.77.2.264","article-title":"Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"issue":"12","key":"10.6061\/clinics\/2018\/e490s_bib58","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/j.1572-0241.2004.40507.x","article-title":"Carcinoid tumors and fibrosis: an association with no explanation","volume":"99","author":"Modlin","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.6061\/clinics\/2018\/e490s_bib59","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/00365528809090760","article-title":"Clinical presentation and prognosis of gastrointestinal carcinoid tumours","volume":"23","author":"Sj\u00f6blom","year":"1988","journal-title":"Scand J Gastroenterol"},{"issue":"18","key":"10.6061\/clinics\/2018\/e490s_bib60","first-page":"5969","article-title":"Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas","volume":"50","author":"Reubi","year":"1990","journal-title":"Cancer Res"},{"issue":"9","key":"10.6061\/clinics\/2018\/e490s_bib61","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocr Pract"},{"issue":"28","key":"10.6061\/clinics\/2018\/e490s_bib62","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e490s_bib63","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.6061\/clinics\/2018\/e490s_bib64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1758834016675803","article-title":"Refractory carcinoid syndrome: a review of treatment options","volume":"9","author":"Riechelmann","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"Suppl","key":"10.6061\/clinics\/2018\/e490s_bib65","article-title":"A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs","volume":"31","author":"Wolin","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.6061\/clinics\/2018\/e490s_bib66","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study","volume":"19","author":"Strosberg","year":"2014","journal-title":"Oncologist"},{"issue":"3","key":"10.6061\/clinics\/2018\/e490s_bib67","first-page":"326","article-title":"Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses","volume":"35","author":"Ferolla","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"10.6061\/clinics\/2018\/e490s_bib68","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1023\/A:1008383132024","article-title":"Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide","volume":"11","author":"Ricci","year":"2000","journal-title":"Ann Oncol"},{"issue":"5","key":"10.6061\/clinics\/2018\/e490s_bib69","first-page":"1381","article-title":"Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e490s_bib70","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198307213090301","article-title":"Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome","volume":"309","author":"Oberg","year":"1983","journal-title":"N Engl J Med"},{"issue":"8","key":"10.6061\/clinics\/2018\/e490s_bib71","first-page":"15","article-title":"Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127)","volume":"13","author":"SWOG S0518","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5-6","key":"10.6061\/clinics\/2018\/e490s_bib72","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12672-015-0233-2","article-title":"Symptomatic Control of Neuroendocrine Tumours with Everolimus","volume":"6","author":"Bainbridge","year":"2015","journal-title":"Horm Cancer"},{"issue":"9808","key":"10.6061\/clinics\/2018\/e490s_bib73","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.6061\/clinics\/2018\/e490s_bib74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J Am Coll Surg"},{"issue":"4","key":"10.6061\/clinics\/2018\/e490s_bib75","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1072-7515(00)00222-2","article-title":"Hepatic neuroendocrine metastases: does intervention alter outcomes?","volume":"190","author":"Chamberlain","year":"2000","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10.6061\/clinics\/2018\/e490s_bib76","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1072-7515(98)00099-4","article-title":"Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?","volume":"187","author":"Chen","year":"1998","journal-title":"J Am Coll Surg"},{"issue":"6","key":"10.6061\/clinics\/2018\/e490s_bib77","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jso.24563","article-title":"Neuroendocrine liver metastasis: The chance to be cured after liver surgery","volume":"115","author":"Bagante","year":"2017","journal-title":"J Surg Oncol"},{"issue":"6","key":"10.6061\/clinics\/2018\/e490s_bib78","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1477-2574.2010.00198.x","article-title":"Long-term survival after surgical management of neuroendocrine hepatic metastases","volume":"12","author":"Glazer","year":"2010","journal-title":"HPB (Oxford)"},{"issue":"8","key":"10.6061\/clinics\/2018\/e490s_bib79","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1245\/s10434-017-5839-x","article-title":"Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database","volume":"24","author":"Fairweather","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"10.6061\/clinics\/2018\/e490s_bib80","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000051860","article-title":"Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors","volume":"62","author":"Ruszniewski","year":"2000","journal-title":"Digestion"},{"issue":"1","key":"10.6061\/clinics\/2018\/e490s_bib81","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/107327480601300110","article-title":"Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors","volume":"13","author":"Strosberg","year":"2006","journal-title":"Cancer Control"},{"issue":"4","key":"10.6061\/clinics\/2018\/e490s_bib82","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00130404-200307000-00008","article-title":"Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience","volume":"9","author":"Gupta","year":"2003","journal-title":"Cancer J"},{"key":"10.6061\/clinics\/2018\/e490s_bib83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2016.01.009","article-title":"Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up","volume":"58","author":"H\u00f6rsch","year":"2016","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.6061\/clinics\/2018\/e490s_bib84","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.6061\/clinics\/2018\/e490s_bib85","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1053\/ejso.2001.1132","article-title":"(131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome","volume":"27","author":"Pathirana","year":"2001","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.6061\/clinics\/2018\/e490s_bib86","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.1996.14.6.1829","article-title":"Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors","volume":"14","author":"Taal","year":"1996","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.6061\/clinics\/2018\/e490s_bib87","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary","volume":"95","author":"Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"21","key":"10.6061\/clinics\/2018\/e490s_bib88","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1161\/CIRCULATIONAHA.105.553750","article-title":"Prognosis of carcinoid heart disease: analysis of 200 cases over two decades","volume":"112","author":"M\u00f8ller","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"10.6061\/clinics\/2018\/e490s_bib89","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000313596","article-title":"Evaluation of treatment with bosentan in patients with carcinoid heart disease: single center study","volume":"33","author":"Lafaras","year":"2010","journal-title":"Onkologie"},{"issue":"2","key":"10.6061\/clinics\/2018\/e490s_bib90","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0735-1097(94)00374-Y","article-title":"Outcome of cardiac surgery for carcinoid heart disease","volume":"25","author":"Connolly","year":"1995","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222011310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222011310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:00:00Z","timestamp":1761721200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222011310"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322018000200312&lng=en&nrm=iso&tlng=en","label":"SCIELO"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/carcinoid-syndrome-update-on-the-pathophysiology-and-treatment\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":90,"alternative-id":["S1807593222011310"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2018\/e490s","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carcinoid syndrome: update on the pathophysiology and treatment","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2018\/e490s","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e490s"}}